# Rallybio Corp: overview

RLYB · Nasdaq · CIK 1739410 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rlyb.md) · [Financials](/companies/rlyb/financials.md) · [Filings](/companies/rlyb/filings.md) · [Insiders](/companies/rlyb/insiders.md)

Latest reported revenue: [$0](/filings/0001628280-26-067422.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 27, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-067422).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [38.0 d](/filings/0001628280-26-018261.md) | [212](/filings/0001628280-26-034580.md) | [212](/filings/0001628280-26-053880.md) | [212](/filings/0001628280-26-067422.md) | [222 d](/filings/0001628280-26-018261.md) | [212](/filings/0001628280-26-034580.md) | [0.0](/filings/0001628280-26-053880.md) | [0.0](/filings/0001628280-26-067422.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(30547.4%) d](/filings/0001628280-26-018261.md) | [(4561.3%)](/filings/0001628280-26-034580.md) | [(4743.9%)](/filings/0001628280-26-053880.md) | [(3266.5%)](/filings/0001628280-26-067422.md) | [(2888.3%) d](/filings/0001628280-26-018261.md) | [(4119.3%)](/filings/0001628280-26-034580.md) | not reported | not reported |
| Net margin | % | [(29063.2%) d](/filings/0001628280-26-018261.md) | [(4452.4%)](/filings/0001628280-26-034580.md) | [(4576.9%)](/filings/0001628280-26-053880.md) | [7554.7%](/filings/0001628280-26-067422.md) | [(2636.0%) d](/filings/0001628280-26-018261.md) | [(3904.7%)](/filings/0001628280-26-034580.md) | not reported | not reported |
| Diluted EPS | $ per share | not reported | [(1.69)](/filings/0001628280-26-034580.md) | [(0.22)](/filings/0001739410-25-000112.md) | [2.84](/filings/0001628280-26-067422.md) | not reported | [(1.46)](/filings/0001628280-26-034580.md) | [7.53](/filings/0001628280-26-053880.md) | [(0.48)](/filings/0001628280-26-067422.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.6](/filings/0001628280-26-018261.md) | [0.9](/filings/0001628280-26-018261.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | [(9511.9%)](/filings/0001628280-26-018261.md) | [(3853.6%)](/filings/0001628280-26-018261.md) |
| Net margin | % | not reported | not reported | not reported | [(9084.1%)](/filings/0001628280-26-018261.md) | [(1046.4%)](/filings/0001628280-26-018261.md) |
| Diluted EPS | $ per share | [(1.84)](/filings/0000950170-23-006264.md) | [(2.09)](/filings/0001739410-24-000035.md) | [(1.84)](/filings/0001739410-25-000040.md) | [(10.61)](/filings/0001628280-26-018261.md) | [(1.59)](/filings/0001628280-26-018261.md) |
| Free cash flow | $m | [(45.9)](/filings/0000950170-23-006264.md) | [(57.3)](/filings/0001739410-24-000035.md) | [(60.3)](/filings/0001739410-25-000040.md) | [(49.3)](/filings/0001628280-26-018261.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rlyb/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-27 | [Lieber Jonathan I](/insiders/1350090.md) | Chief Financial Officer, Officer | Sale (S) | 599 | $16.04 | $9.6k | [Form 4](/filings/0001193125-26-436314.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $14.8m | 926,352 |  | Added +905,817 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $12.7m | 7,705,787 |  | Added +7,685,901 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $12.7m | 794,720 |  | Added +1,269 |
| [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $8.4m | 524,347 |  | Unchanged |
| [TPG GP A, LLC](/funds/1903793.md) | 2026-06-30 | $6.1m | 378,551 |  | Unchanged |
| [Pivotal bioVenture Partners Investment Advisor LLC](/funds/1844645.md) | 2026-06-30 | $4.8m | 300,579 |  | Unchanged |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $3.2m | 199,907 |  | Added +43,380 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $3.0m | 188,422 |  | Reduced −112,213 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $3.0m | 188,422 |  | Reduced −112,213 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.8m | 172,497 |  | Added +60,457 |

## Recent filings

[All 300 filings](/companies/rlyb/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-27 | 08:08 ET | [10-Q](/filings/0001628280-26-067422.md) | Quarterly report, period 2026-09-30 | 0001628280-26-067422 |
| 2026-10-26 | 16:53 ET | [8-K](/filings/0001193125-26-432114.md) | 8.01 Other events | 0001193125-26-432114 |
| 2026-09-09 | 16:30 ET | [8-K](/filings/0001193125-26-386511.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-386511 |
| 2026-08-06 | 08:03 ET | [10-Q](/filings/0001628280-26-053880.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053880 |
| 2026-06-01 | 08:07 ET | [8-K](/filings/0001193125-26-249790.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-249790 |
| 2026-05-13 | 16:01 ET | [10-Q](/filings/0001628280-26-034580.md) | Quarterly report, period 2026-03-31 | 0001628280-26-034580 |
| 2026-05-06 | 16:51 ET | [SCHEDULE 13D/A](/filings/0001674324-26-000004.md) | Ownership report, active investor, amended | 0001674324-26-000004 |
| 2026-05-04 | 07:54 ET | [8-K](/filings/0001193125-26-202601.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-202601 |
| 2026-03-31 | 16:08 ET | [8-K](/filings/0001628280-26-022385.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-022385 |
| 2026-03-16 | 17:18 ET | [10-K](/filings/0001628280-26-018261.md) | Annual report, period 2025-12-31 | 0001628280-26-018261 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-018261.md), filed Mar 16, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/055a4925-5185-4dcf-852b-f5575f9d2ea1)

## About the filer

- CIK: 1739410
- Tickers: RLYB
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 18:07 ET. No prices; not investment advice.